Laurus Labs Ltd
NSE:LAURUSLABS
Operating Margin
Laurus Labs Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| IN |
|
Laurus Labs Ltd
NSE:LAURUSLABS
|
444.9B INR |
11%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
722.3B USD |
40%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
395.4B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK |
45%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
201.9B CHF |
33%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
177.3B CHF |
33%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
158.5B GBP |
24%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
199.6B USD |
34%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.8B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
137.9B USD |
27%
|
Laurus Labs Ltd
Glance View
Laurus Labs Ltd., an Indian pharmaceutical powerhouse, has etched its presence in the global pharma industry with a focus on delivering affordable and high-quality active pharmaceutical ingredients (APIs). Founded in 2005, the company's trajectory has been nothing short of remarkable, with an emphasis on research-driven production and sustainability. The Hyderabad-based conglomerate cultivates its core expertise within key therapeutic areas such as antiviral, cardiovascular, and oncology medications. By amalgamating scientific prowess with cutting-edge manufacturing facilities, Laurus Labs has positioned itself as a fundamental supplier in the fight against global ailments, providing APIs to some of the most critical generic pharmaceuticals worldwide. The company's commitment to health innovation is reflected in its robust portfolio of over 60 commercialized APIs, substantiating its pivotal role in the pharmaceutical supply chain. Adding another feather to its cap, Laurus Labs has ventured into the formulation business, manufacturing finished dosage forms that reach consumers directly. This vertical integration allows Laurus to capture a larger share of the pharmaceutical value chain, maximizing returns from its research and manufacturing capabilities. The company's foray into generic formulations has opened doors to new markets, particularly in challenging economies where cost-effective treatment is crucial. By leveraging its API expertise to produce effective, high-quality generic medications, Laurus Labs not only enhances its profitability but also adheres to its founding ethos of making healthcare accessible. With investments in research and development and a commitment to expanding its product line, Laurus Labs continues to strengthen its presence while nurturing partnerships globally, fueling its growth trajectory.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Laurus Labs Ltd's most recent financial statements, the company has Operating Margin of 11.3%.
You don't have any saved screeners yet